GENOVIS AB Tromsø, May 3[rd] 2023 -ArcticZymes Technologies ASA (OSE: AZT) andGenovis are excited to announce a collaboration to speed up penetration and growth in the Chinese market. The collaboration will create several synergies that will allow both companies to tap into the projected growth potential inChina for their respective market segments. The focus of the collaboration will be on sharing Business Development resources and engaging in joint Marketing activities. The joint effort will allow both companies to have a direct presence in the Chinese market with local resources. According to Dirk Hahneiser, VP ofBusiness Development & Marketing ,ArcticZymes : "Sharing our resources will not only leverage economies of scale, increased profitability, and long-term value creation for shareholders, but also frees up resources to focus even more on our customers and their needs."Rikke Rytter , VP Sales & Marketing atGenovis , says, "We're excited about the collaboration because joining forces enables both Nordic enzyme companies to leverage synergies, amplify impact, mitigate risk, and expand our respective presence in this fast-growing market." For more information, please contact:ArcticZymes Technologies ASA CFO, Børge Sørvoll Tel: +47 952 90187 ir@arcticzymes.comGenovis AB CEO,Fredrik Olsson Tel: +46 (0)70 276 46 56 fredrik.olsson@genovis.com AboutArcticZymes Technologies ASA ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research,In Vitro Diagnostics (IVD) and biomanufacturing. The company is listed on theOslo Stock Exchange since 2005 asArcticZymes Technologies under the [AZT] ticker. Its headquarters are based in Tromsø,Norway , at the SIVA Innovation Centre.ArcticZymes Technologies' IP and capabilities are protected via a large portfolio of patents. For more information, please visit the website: www.arcticzymes.com. AboutGenovis AB Genovis' business concept is to apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future. TodayGenovis sells several enzyme products known as SmartEnzymesT all over the world in innovative product formats that facilitate development and quality control of biological drugs. The Group consists ofGenovis AB and the wholly owned subsidiaryGenovis Inc. (US).Genovis shares are listed onNasdaq First North Growth Market andErik Penser Bank is the Company's Certified Adviser, certifiedadviser@penser.se, tel: +46 (0)8-463 83 00.
Click here for more information
© Oslo Bors ASA, source
